KRAS and cancer: Therefore, in the present study, we explore the therapeutic potential of bioflavonoids against the KRAS G12D mutant by examining their drug-likeness properties, ADME properties, binding affinities, steered molecular dynamics, molecular-dynamics simulation, possible activity against kinases, toxicity, and in silico cancer-cell-line cytotoxicity profiles.